EXELIXIS, INC. · Biotech

EXEL

Low riskNext report: In 7 days (est.)

View price ↗

The short version

A high-quality, profitable business with growing sales.

Going well

Sales up 11% in the latest quarter vs a year ago
Profitable, keeps 34% of sales as profit
Brings in more cash than it spends

Money moves

No insider buying or selling in the last 30 days
Institutions added 0.8% to their holdings in the quarter ending June 2026 (379 bought, 339 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$65.12+0.9% that day

Company value: $16.1B; Share price times all shares
Price vs profit (P/E): 20.5x; You pay about $20 for each $1 of yearly profit
Price vs sales: 6.6x; Company value is 6.6 times a year of sales
Cash vs value: 2%; Cash as a share of company value

From EXEL's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jul '26

$628.7M+11% vs a year earlier

Sep '23Tap a barJul '26

Last 12 months: $2.4B, up 9.2% from the 12 months before. Over 5 years, sales grew about 19% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of EXEL. Starting points are the company's recent numbers.

Sales growth+9% a yearRecently: +9.2% a yearProfit margin35%Last 12 months: 35.3%P/E at the end20xToday: 20.5x. Many steady companies trade at 12x to 25xShare count change-4% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$3.7B

Profit in 5 years$1.3B

Price these guesses point to$129.86+99% vs $65.12 todayAbout +15% a year, before dividends

What today's price needs: with a 35% margin and a 20x P/E, sales could shrink about 5.1% a year for 5 years and still match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

5/6Strong

PassReturn on equity 15%+Earns a lot on the money owners have in the business.35.5%
PassDebt under half of equityNot relying on borrowed money.No debt reported
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.33.7%
MissProfitable every yearSteady profits, not one good year.9 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$875.8M
PassShare count not growingNot diluting owners. Falling means buybacks.-13.2% in 3 years

Revenue: $2.3B; +7.0% vs prior year
5-year growth: +18.6%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 3.56x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jul 3, 2026

Reported Aug 5

Revenue: $628.7M; +10.6% YoY
EPS: $0.82; vs $0.65
Op. margin: 39.5%; +1.9 pts
Gross margin: 96.7%; +0.1 pts
Free cash flow: $300.9M
Share count: -8.7%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.7
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Steady+0.8%

Institutions added 0.8% to their holdings. 379 bought, 339 sold.

Shares held by institutions259.8M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

-8.0%

Cash runwayAt last year's cash burn

Cash flow positive

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

248M

Earnings reports

Last 12

Next reportIn 7 days (est.)Estimated from the same quarter last year

Results filedAug 5
Results filedMay 5
Results filedFeb 10
Results filedJan 12
Results filedNov 4, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (active)Aug 14 · View filing ↗Activist 5%+ holder update (passive)Aug 12 · View filing ↗Big holder

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Other company newsSep 11 · Form 8-K ↗Other company newsAug 31 · Form 8-K ↗5%+ holder update (active)Aug 14 · Form SCHEDULE 13D/A ↗5%+ holder update (passive)Aug 12 · Form SCHEDULE 13G/A ↗

SoldMary C BeckerleDirector

9,812 shares at $53.66 · $527K

-38% of holdings
Now owns 16,079 shares
Pre-planned sale (10b5-1)
Filed 2 days after trade

Aug 10Form 4 ↗

Planned insider saleAug 10 · Form 144 ↗Earnings resultsAug 5 · Form 8-K ↗Quarterly reportAug 5 · Form 10-Q ↗Employee stock plan registrationAug 5 · Form S-8 ↗

SoldSue Gail EckhardtDirector

9,812 shares at $50.14 · $492K

-38% of holdings
Now owns 16,079 shares
Pre-planned sale (10b5-1)
Filed 2 days after trade

Jun 1Form 4 ↗

SoldJack L WyszomierskiDirector

3,925 shares at $50.55 · $198K

-1% of holdings
Now owns 284,384 shares
Pre-planned sale (10b5-1)
Filed 2 days after trade

Jun 1Form 4 ↗

Planned insider saleJun 1 · Form 144 ↗Planned insider saleJun 1 · Form 144 ↗Leadership changeMay 29 · Form 8-K ↗

Stock awardDavid Edward JohnsonDirector

19,133 shares

Now owns 19,133 shares
Exercise price $50.03
Option (right to buy)
Filed 2 days after trade
Joint filing with 1 other

May 27Form 4 ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page